<DOC>
	<DOCNO>NCT00555750</DOCNO>
	<brief_summary>The purpose study test effect sleep eszopiclone , drug help people sleep , body process glucose ( sugar ) . Eszopiclone approve U.S. Food Drug Administration ( FDA ) sale treatment insomnia . It market United States LUNESTA . Main Hypothesis : Primary insomnia associate impairment glucose metabolism reverse two month eszopiclone primary insomnia</brief_summary>
	<brief_title>Sleep Loss Mechanisms Impaired Glucose Metabolism</brief_title>
	<detailed_description>Insomnia common sleep disorder , affect nearly one-third adult give year , chronically affect 10-15 % adult population . Reduced sleep time , independent insomnia , associate variety deleterious long term effect , include increase risk incident myocardial infarction symptomatic diabetes . Chronic partial sleep loss insomnia may impair glucose metabolism short term associate development diabetes long term . Although extent sleep loss acute laboratory-based 'sleep debt ' study healthy volunteer , chronic primary insomnia patient exhibit 'hyperarousal ' ( hypercortisolemia afternoon evening , accelerate metabolism ) similar see acute sleep deprivation . In addition , degradation sleep quantity quality primary insomnia attribute cognitive somatic hyperarousal sleep setting . study examines quantifies adult men woman link primary insomnia impair glucose tolerance . This study examine extent adequate treatment primary insomnia reverse impairment glucose metabolism . If abnormality glucose metabolism reversible , study demonstrate importance treatment chronic primary insomnia .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Age 2555 Complaint insomnia least 6 month duration DSMIV diagnosis Primary Insomnia Sleep diary : mean Total Sleep Time &lt; 6 hour mean total wake time ( sleep latency + wake sleep onset ) great 60 minute ( previous 14 day record sleep diary ) A willingness comply study procedure If childbearing potential , use medicallyaccepted method birth control , include abstinence , barrier method spermicide , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method , intrauterine device [ IUD ] ) Current diagnosis DSMIV Axis I disorder Primary Insomnia Regular treatment ( 1 time/week ) CNS active medication within 1 month fist inpatient visit Treatment medication interfere glucose metabolism include antidiabetic medication steroidal contraceptive Uncontrolled medical illness would interfere participation study Body Mass Index &gt; 32 &lt; 19.8 Current symptom diagnosis moderate severe sleep disorder insomnia No menopausal perimenopausal symptom disrupt sleep Pregnant , lactate plan become pregnant Consumption &gt; 2 caffeinated beverage per day ( include coffee , tea and/or caffeinecontaining beverage food ) 3 week prior start study</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>sleep</keyword>
	<keyword>metabolism</keyword>
	<keyword>insulin</keyword>
	<keyword>glucose</keyword>
	<keyword>actigraphy</keyword>
	<keyword>diary</keyword>
	<keyword>volumetry</keyword>
	<keyword>GABA</keyword>
</DOC>